{"url_path":"/sec/avln/8-k/2026-06-03/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-254581-index.html","accession_number":"0001193125-26-254581","cik":"0001540171","ticker":"AVLN","issuer_name":"Avalyn Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-254581-index.html","primary_entity_key":"0001540171","primary_entity_name":"Avalyn Pharma Inc."},"word_count":136,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn June 3, 2026, Avalyn Pharma Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information included under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}